You are here

  • Home
  • Archive
  • Volume 11, Issue 10
  • Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective study

Article info

Article menu
Case report
Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective study

Authors

  • Khinh Ranh Voong Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Peter B Illei Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Bradley Presson Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USABloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Dipika Singh Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USABloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USAThe Mark Foundation Center for Advanced Genomics and Imaging, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Zhen Zeng Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USABloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USAThe Mark Foundation Center for Advanced Genomics and Imaging, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Mara Lanis Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Russell K Hales Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Chen Hu Division of Quantitative Sciences, Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Phuoc T Tran Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland, USADepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Christos Georgiades Department of Radiology, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Cheng Ting Lin Department of Radiology, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Jeffrey Thiboutout Department of Pulmonology, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Julie R Brahmer Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USABloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Patrick M Forde Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USABloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Jarushka Naidoo Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USABloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USABeaumont Hospital, Dublin, IrelandRCSI University of Medicine and Health Sciences, Dublin, Ireland PubMed articlesGoogle scholar articles
  • Valsamo Anagnostou Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Kellie N Smith Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USABloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USAThe Mark Foundation Center for Advanced Genomics and Imaging, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles

Citation

Voong KR, Illei PB, Presson B, et al
Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective study
Journal for ImmunoTherapy of Cancer 2023;11:e007188. doi: 10.1136/jitc-2023-007188
Online issue publication 
October 04, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.